Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 4/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13757742 | 0.91 | CHRM4 (0.57) | CHRM4GPR119DRD2DRD3NOTCH1 | |
| SCHEMBL688078 | 0.86 | GPR119 (0.56) | CHRM4GPR119DRD2DRD3MGLL | |
| SCHEMBL14624177 | 0.86 | GPR119 (0.57) | GPR119DRD2TGFBR1CNR1 | |
| SCHEMBL27380076 | 0.86 | GPR119 (0.57) | CHRM4GPR119DRD2TGFBR1CNR1 | |
| SCHEMBL3487620 | 0.86 | GPR119 (0.72) | CHRM4GPR119NOTUM | |
| SCHEMBL13926625 | 0.82 | ALDH1A1 (0.57) | GPR119TGFBR1CNR1 | |
| SCHEMBL20141419 | 0.82 | GPR119 (0.52) | CHRM4GPR119DRD2DRD3MGLL | |
| SCHEMBL30981434 | 0.82 | GPR119 (0.57) | GPR119TGFBR1CNR1 | |
| SCHEMBL27380046 | 0.80 | YAP1 (0.54) | CHRM4GPR119 | |
| SCHEMBL30981386 | 0.80 | HRH1 (0.55) | GPR119TGFBR1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | CHRM4 522/4885GPR119 1/4885DRD2 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.